BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 34641391)

  • 1. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy.
    Tong JTW; Harris PWR; Brimble MA; Kavianinia I
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates-A Tutorial Review.
    Baah S; Laws M; Rahman KM
    Molecules; 2021 May; 26(10):. PubMed ID: 34063364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepping forward in antibody-drug conjugate development.
    Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
    Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
    Chia CSB
    ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
    Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
    Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
    Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
    Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody drug conjugate: the "biological missile" for targeted cancer therapy.
    Fu Z; Li S; Han S; Shi C; Zhang Y
    Signal Transduct Target Ther; 2022 Mar; 7(1):93. PubMed ID: 35318309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-Drug Conjugates: The New Frontier of Chemotherapy.
    Ponziani S; Di Vittorio G; Pitari G; Cimini AM; Ardini M; Gentile R; Iacobelli S; Sala G; Capone E; Flavell DJ; Ippoliti R; Giansanti F
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32752132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Antibody-Drug Conjugates: Future Perspective Towards Solid Tumor Treatment.
    Pramanik D
    Anticancer Agents Med Chem; 2023; 23(6):642-657. PubMed ID: 36321237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug conjugate-based anticancer therapy - Current status and perspectives.
    Yang Y; Wang S; Ma P; Jiang Y; Cheng K; Yu Y; Jiang N; Miao H; Tang Q; Liu F; Zha Y; Li N
    Cancer Lett; 2023 Jan; 552():215969. PubMed ID: 36279982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in antibody-drug conjugates: A new era of targeted cancer therapy.
    Sau S; Alsaab HO; Kashaw SK; Tatiparti K; Iyer AK
    Drug Discov Today; 2017 Oct; 22(10):1547-1556. PubMed ID: 28627385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
    Liao MZ; Lu D; Kågedal M; Miles D; Samineni D; Liu SN; Li C
    Clin Pharmacol Ther; 2021 Nov; 110(5):1216-1230. PubMed ID: 33899934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.